Evidence map›Paper›PMID 28066708›Full record

Trial reportNeuroImage. Clinical2017

Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers.

Andrew S Kayser, Taylor Vega, Dawn Weinstein, Jan Peters, Jennifer M Mitchell

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02772978 (A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors in PPG), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02772978 nacompletednot on this map

A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors in PPG

TypeinterventionalSponsorUniversity of California, San FranciscoRan2014 to 2015Enrolled19ConditionsPathological GamblingArmsTolcapone, Placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  4. Cortical dopamine reduces the impact of motivational biases governing automated behaviour.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Prefrontal and striatal dopamine DBrain imaging and behavior · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Andrew S KayserDepartment of Neurology, University of California, San Francisco, United States; Department of Neurology, VA Northern California Health Care System, United States.
Taylor VegaDepartment of Neurology, VA Northern California Health Care System, United States.
Dawn WeinsteinDepartment of Neurology, University of California, San Francisco, United States.
Jan PetersDepartment of Psychology, University of Cologne, Germany.
Jennifer M MitchellDepartment of Neurology, University of California, San Francisco, United States; Department of Psychiatry, University of California, San Francisco, United States.
University of California, San Francisco · USUniversity of Cologne · DEVA Northern California Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Failures of self-regulation in problem and pathological gambling (PPG) are thought to emerge from failures of top-down control, reflected neurophysiologically in a reduced capacity of prefrontal cortex to influence activity within subcortical structures. In patients with addictions, these impairments have been argued to alter evaluation of reward within dopaminergic neuromodulatory systems. Previously we demonstrated that augmenting dopamine tone in frontal cortex via use of tolcapone, an inhibitor of the dopamine-degrading enzyme catechol-O-methyltransferase (COMT), reduced delay discounting, a measure of impulsivity, in healthy subjects. To evaluate this potentially translational approach to augmenting prefrontal inhibitory control, here we hypothesized that increasing cortical dopamine tone would reduce delay discounting in PPG subjects in proportion to its ability to augment top-down control. To causally test this hypothesis, we administered the COMT inhibitor tolcapone in a randomized, double-blind, placebo-controlled, within-subject study of 17 PPG subjects who performed a delay discounting task while functional MRI images were obtained. In this subject population, we found that greater BOLD activity during the placebo condition within the right inferior frontal cortex (RIFC), a region thought to be important for inhibitory control, correlated with greater declines in impulsivity on tolcapone versus placebo. Intriguingly, connectivity between RIFC and the right striatum, and not the level of activity within RIFC itself, increased on tolcapone versus placebo. Together, these findings support the hypothesis that tolcapone-mediated increases in top-down control may reduce impulsivity in PPG subjects, a finding with potential translational relevance for gambling disorders, and for behavioral addictions in general.

Indexed as

Prefrontal CortexVentral StriatumAdultBenzophenonesCatechol O-Methyltransferase InhibitorsConnectomeDelay DiscountingDouble-Blind MethodFemaleGamblingHumansMagnetic Resonance ImagingMaleMiddle AgedNitrophenolsTolcaponeBenzophenonesCatechol O-Methyltransferase InhibitorsNitrophenolsTolcaponeDopamineFrontostriatalGamblingPrefrontal cortexTolcaponeVentral striatum

Identifiers

PMID28066708
PMCPMC5200917
OpenAlexW2567076700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.